Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | SP1 | P08047 | 1/20 | 0.54 |
| ▸ | ILF3 | Q12906 | 1/20 | 0.54 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | KCNK13 | Q9HB14 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191592 | 0.88 | BIRC5 (0.49) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6188964 | 0.88 | BIRC5 (0.48) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6189657 | 0.87 | BIRC5 (0.47) | BIRC5RIPK2SP1ILF3PAK1 | |
| Hydrochloric Acid SCHEMBL6187073 | 0.86 | BIRC5 (0.52) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6189591 | 0.86 | BIRC5 (0.49) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6188763 | 0.85 | BIRC5 (0.50) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6187056 | 0.84 | BIRC5 (0.58) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL6188375 | 0.83 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29464041 | 0.83 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6188546 | 0.83 | BIRC5 (0.64) | BIRC5RIPK2SP1ILF3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1256576-B1 | FUSED IMIDAZOLIUM DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | claimed |
| US-6734203-B2 | ANTI-CANCERS AND ANTITUMOR AGENTS | ASTELLAS PHARMA INC. (JP) | 2004-05-11 | — | — | US | claimed |
| US-20030114508-A1 | Fused imidazolium derivatives | ASTELLAS PHARMA INC. (JP) | 2003-06-19 | — | — | US | claimed |
| EP-1256576-A1 | FUSED IMIDAZOLIUM DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-11-13 | — | — | EP | claimed |
| EP-1256576-B1 | FUSED IMIDAZOLIUM DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6734203-B2 | ANTI-CANCERS AND ANTITUMOR AGENTS | ASTELLAS PHARMA INC. (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030114508-A1 | Fused imidazolium derivatives | ASTELLAS PHARMA INC. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1256576-A1 | FUSED IMIDAZOLIUM DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114508-A1 | Fused imidazolium derivatives | TP53, HRAS, BCOR | BIRC5 53/4885RIPK2 408/4885SP1 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.